Advances in the Management of Colorectal Cancer: A Latin-American Perspective

  • A free symposium hosted by Springer Healthcare, in São Paulo, Brazil, Saturday, 29th November 2014

    Aims
    The aim of the symposium is to provide quality education focused, in particular, on the majority of Latin American oncologists, gastroenterologists and gastric surgeons who are unable to attend the 2014 ESMO meeting.

    The meeting brochure can be found here.

    Presentations from the 2014 ESMO Congress have been selected by the Scientific Programme Panel on the basis of meeting the identified learning objectives.

    Watch the full video presentations here.

    Each individual part of a session will comprise a video abstract interview discussing the background, methods, results and key discussion points of the ESMO talk shown concomitantly with slides of these points. The Chair of the overall session will then summarise and reiterate the key points of the talk as the starting point for a panel discussion amongst the meeting Faculty on the talk’s implications for the Latin-American region with respect to current local CRC management protocols and guidelines. A question and answers session with the audience will complete each slot.

    The case studies will comprise the presentation of case studies submitted by the delegates in advance of the symposium followed by a panel discussion amongst the meeting Faculty of the study and a question and answers session with the audience.

    Learning objectives
    Upon participation in this activity, attendees will be able to:

    • Provide detailed information on the latest developments in classifying the subclasses of colorectal cancer and the potential clinical applications of these subtypes and how they apply in a Latin-American context.
    • Provide detailed information on the state-of-the-art tools available for directing adjuvant chemotherapy for colorectal cancer and how they apply in a Latin-American context
    • Provide detailed information on the latest guidelines for identifying the correct chemotherapy agent when treating metastatic colorectal cancer and how they apply in a Latin-American context
    • Provide detailed information on how epigenetics can be used to inform the design of novel combinatorial therapies tailored on the combined epigenetic and genetic make-up of specific tumour subtypes, the latest developments in pipeline molecular therapies targeting specific oncoprotein-mediated signaling cascades, and how peptide-based cancer vaccines and immune-enhancers can be used in the treatment of colorectal cancer and how they apply in a Latin-American context.
    • Provide detailed information on how the determination of biomarkers such as protein expression profiles might predict treatment response or prognosis in colorectal cancer, how colorectal cancer tumours can be diagnosed and classified on the basis of their genetic profiles and how the pattern of genetic alterations present in individual cancers can, at least in part, be used to predict their clinical outcome and how they apply in a Latin-American context.


    Target audience
    Local oncologists, gastroenterologists and gastric surgeons from around the Latin-American region.

    CME accreditation
    The ‘Advances in the Management of Colorectal Cancer: A Latin-American Perspective ‘ is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

    The ‘Advances in the Management of Colorectal Cancer: A Latin-American Perspective ‘ is designated for a maximum of (or ‘for up to’) 6 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

    Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

    Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

    Language
    The official language of the symposium will be English.

    shimeLogoHeader

    Springer Healthcare works with a network of medical experts and societies to identify knowledge gaps across a multitude of disease areas. We create learning programs and initiatives to address these gaps. Springer Healthcare increases knowledge in disease awareness through wholly independent content solutions.

  • Programme
    Welcome and opening address – Paulo Hoff (Symposium Chair)
    A new molecular taxonomy for colorectal cancer – What are the therapeutic implications?
    Presented at ESMO 2014 by Ultan McDermott; summarised by Alberto Sobrero

    Liquid biopsies and “on treatment” markers
    Presented at ESMO 2014 by Gerald Prager; summarised by Alberto Sobrero

    Panel discussion: Paulo Hoff, Anelisa Coutinho, Paulo Herman and Enrique Roca
    Are there any useful tools when deciding about adjuvant chemotherapy?
    Presented at ESMO 2014 by Richard Adams; summarised by Alberto Sobrero

    Final results from QUASAR2, a multicentre, international randomised phase III trial of capecitabine (CAP) +/- bevacizumab (BEV) in the adjuvant setting of stage II/III colorectal cancer (CRC)
    Presented at ESMO 2014 by Rachel Midgely; summarised by Alberto Sobrero

    Panel discussion: Paulo Hoff, Anelisa Coutinho, Paulo Herman and Enrique Roca
    Case studies
    How to select first line chemotherapy in metastatic colorectal cancer
    Presented at ESMO 2014 by Claus-Henning Koehne; summarised by Alberto Sobrero

    CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum
    Presented at ESMO 2014 by Heinz-Joseph Lenz; summarised by Alberto Sobrero

    CALGB/SWOG 80405: Analysis of patients undergoing surgery as part of treatment strategy
    Presented at ESMO 2014 by Alan Venook; summarised by Alberto Sobrero

    Panel discussion: Paulo Hoff, Anelisa Coutinho, Paulo Herman and Enrique Roca
    Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population
    Presented at ESMO 2014 by Sebastian Stintzing; summarised by Alberto Sobrero

    Panel discussion: Paulo Hoff, Anelisa Coutinho, Paulo Herman and Enrique Roca
    Phase III RECOURSE trial of TAS-102 vs. placebo, with best supportive care (BSC), in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies
    Presented at ESMO 2014 by Eric van Cutsem; summarised by Alberto Sobrero

    Panel discussion: Paulo Hoff, Anelisa Coutinho, Paulo Herman and Enrique Roca
    Closing remarks – Paulo Hoff (Symposium Chair)

  • Educational Grant
    This event has been supported by an independent educational grant from Merck Serono. The financial supporter has not had any influence in the development or presentation of any aspect of this meeting.